Germantown, MD, and Hilden, Germany, July 20th, 2011 – QIAGEN launches the Multiplex PCR Plus Kit, designed for rapid and sensitive multiplex PCR that allows researchers to amplify several targets in one PCR run. The kit provides fast reaction times and comes with a pre-optimized protocol, eliminating the need for optimization and delivering reliable results on the first attempt.
The master mix included with the Multiplex PCR Plus Kit contains the enzyme HotStarTaq® Plus DNA Polymerase, as well as a balanced combination of salts and additives, which increases multiplex reaction specificity and ensures comparable efficiencies for all primers in the PCR reaction. This proprietary technology allows straightforward assay development for many challenging applications, such as detection of mutations or microsatellites and microbial genotyping.
The kit also includes CoralLoad® - a buffer that contains two dyes that improves pipetting visibility during reaction setup, gel loading, and visualization of DNA migration. Therefore, it is no longer necessary to use other dyes for gel electrophoresis. Downstream analysis of the multiplex PCR products can be performed with a variety of methods such as agarose gels, capillary sequencers, as well as multicapillary electrophoresis with the QIAxcel® Advanced System. Find out more about the QIAGEN Multiplex PCR Plus Kit at www.qiagen.com/multiplex-PCR.
For a high-resolution image please contact us at marc.egelhofer@qiagen.com.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN’s assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
